Cargando…

Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells

The Cancer/Testis (CT) antigen family of genes are transcriptionally repressed in most human tissues but are atypically re-expressed in many malignant tumour types. Their restricted expression profile makes CT antigens ideal targets for cancer immunotherapy. As little is known about whether CT antig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagotto, Anna, Caballero, Otavia L., Volkmar, Norbert, Devalle, Sylvie, Simpson, Andrew J. G., Lu, Xin, Christianson, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858345/ https://www.ncbi.nlm.nih.gov/pubmed/24340093 http://dx.doi.org/10.1371/journal.pone.0083212

Ejemplares similares

Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers
por: Raghavendra, Ashwini, et al.
Publicado: (2018)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
por: Freiberger, Sandra N., et al.
Publicado: (2022)

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
por: Matković, Božica, et al.
Publicado: (2011)

Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma
por: Hudolin, Tvrtko, et al.
Publicado: (2013)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
por: Bujas, T., et al.
Publicado: (2011)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
por: Ishihara, Mikiya, et al.
Publicado: (2020)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
por: Iura, Kunio, et al.
Publicado: (2015)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression
por: Hou, Zhenbo, et al.
Publicado: (2020)

Correction: Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
por: Shiohama, Yasuo, et al.
Publicado: (2017)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma
por: Ueda, Shugo, et al.
Publicado: (2018)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

Transient expression of the cancer/testis cancer antigen NY-ESO-1 in Nicotiana benthamiana using a PVX-based viral vector
por: Lacorte, Cristiano, et al.
Publicado: (2014)

Differential Evolution of MAGE Genes Based on Expression Pattern and Selection Pressure
por: Zhao, Qi, et al.
Publicado: (2012)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma
por: Gjerstorff, Morten F, et al.
Publicado: (2013)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A
por: Pourmaleki, Maryam, et al.
Publicado: (2019)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
por: de Carvalho, Fabricio, et al.
Publicado: (2011)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c8387j3g7kd1q1mk3399l1uvqb